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Inﬂammation of adipose tissue in obesity is associated with increased IL-1b, IL-6 and TNF-a secretion and
proposed to contribute to insulin resistance. AMP-activated protein kinase (AMPK) regulates nutrient
metabolism and is reported to have anti-inﬂammatory actions in adipose tissue, yet the mechanisms
underlying this remain poorly characterised. The effect of AMPK activation on cytokine-stimulated
proinﬂammatory signalling was therefore assessed in cultured adipocytes. AMPK activation inhibited
IL-1b-stimulated CXCL10 secretion, associated with reduced interleukin-1 receptor associated kinase-4
(IRAK4) phosphorylation and downregulated MKK4/JNK and IKK/IkB/NFkB signalling. AMPK activation
inhibited TNF-a-stimulated IKK/IkB/NFkB signalling but had no effect on JNK phosphorylation. The JAK/
STAT3 pathway was also suppressed by AMPK after IL-6 stimulation and during adipogenesis. Adipose
tissue from AMPKa1/ mice exhibited increased JNK and STAT3 phosphorylation, supporting suppres-
sion of these distinct proinﬂammatory pathways by AMPK in vivo. The inhibition of multiple pro-
inﬂammatory signalling pathways by AMPK may underlie the reported beneﬁcial effects of AMPK acti-
vation in adipose tissue.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Obesity is associated with chronic low-grade inﬂammation of
white adipose tissue (WAT), inwhich there is upregulated secretion
of the pro-inﬂammatory cytokines TNF-a, IL-1b and IL-6. Plasma
concentrations of these pro-inﬂammatory cytokines have been
reported to be elevated in obese individuals (Lee et al., 2009). TNF-a
and IL-1b trigger pro-inﬂammatory effects via simultaneous acti-
vation of the nuclear factor kappa B (NFkB) and multiple mitogen-
activated protein kinase (MAPK) intracellular signalling pathways.
IL-1b binding leads to recruitment of adapter proteins that furtherg, Netherlands.
r Ireland Ltd. This is an open accesrecruit IL-1 receptor associated kinase (IRAK) family members,
directly interacting with IRAK4 which autophosphorylates and
activates the downstream kinases IRAK1 and IRAK2. IRAK activa-
tion further stimulates formation of a signalosome including TNF
receptor-associated factor-6 (TRAF6), TGFb-activated kinase-1
(TAK1) and IkB kinase (IKK) (Salt and Palmer, 2012). TNF-a en-
gages multiple complex ubiquitin-dependent processes that also
stimulate TAK1 and IKK (Salt and Palmer, 2012). IKK stimulates the
phosphorylation of inhibitor of NFkB (IkBa), targeting IkB for pro-
teasomal degradation and thereby releasing active NFkB dimers,
with p65-p50 heterodimers being the principal form activated by
the canonical NFkB pathway in response toTNF-a and IL-1b (Cohen,
2014; Brenner et al., 2015; Salt and Palmer, 2012). The p65-p50
heterodimers subsequently translocate into the nucleus to bind kB-
responsive elements in the promoters of target genes, includings article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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1b stimulate activation of pro-inﬂammatory MAPKs, such as the c-
jun N-terminal kinase (JNK) pathway, in parallel with NFkB acti-
vation (Cohen, 2014; Salt and Palmer, 2012).
In contrast, IL-6 elicits its effects via binding amembrane-bound
IL-6 receptor complexed with the co-receptor gp130 (classic sig-
nalling), or by binding a soluble IL-6 receptor (sIL-6Ra) that binds to
gp130 (trans-signalling), stimulating Janus kinase (JAK)-mediated
activation of the signal transducer and activator of transcription-3
(STAT3) transcription factor predominantly via phosphorylation
of Tyr705 (Salt and Palmer, 2012; Qu et al., 2014). The cytokine-
stimulated NFkB, JNK and JAK/STAT pathways culminate in the
secretion of multiple pro-inﬂammatory cytokines and chemokines,
including monocyte chemoattractant protein-1 (MCP-1), which
stimulates the activation and inﬁltration of macrophages (Cohen,
2014; Brenner et al., 2015; Salt and Palmer, 2012; Qu et al., 2014).
In adipose tissue, macrophages undergo a shift in polarisation from
an anti-inﬂammatory ‘alternatively activated’ state, to a ‘classically
activated’ pro-inﬂammatory state, which has been reported to
dominate in WAT in obesity (Lumeng et al., 2007).
Increased ATP consumption and/or decreased ATP synthesis,
leads to an increase in ADP:ATP and AMP:ATP ratios that activate
the heterotrimeric Ser/Thr protein kinase AMP-activated protein
kinase (AMPK) (Salt and Palmer, 2012; Bijland et al., 2013). Acti-
vated AMPK phosphorylates target proteins that act to normalise
ATP concentrations by stimulating ATP-generating pathways such
as fatty acid oxidation, mitochondrial biogenesis and muscle
glucose transport, whilst inhibiting ATP-consuming anabolic
pathways including protein translation, fatty acid and cholesterol
synthesis (Salt and Palmer, 2012; Bijland et al., 2013). In adipose
tissue, AMPK suppresses adipogenesis, fatty acid and triglyceride
synthesis (Bijland et al., 2013).
More recently, AMPK has been reported to have anti-
inﬂammatory actions independent of its metabolic effects, dimin-
ishing immune responses in a range of in vivo models of inﬂam-
mation (Salt and Palmer, 2012). Although AMPK-dependent
inhibition of pro-inﬂammatory signalling has been reported in
preadipocytes, macrophages and vascular cells (Jeong et al., 2009;
Sag et al., 2008; Ewart et al., 2008; Chen et al., 2016), all of which
are present in signiﬁcant quantities in intact adipose tissue, AMPK-
dependent suppression of pro-inﬂammatory signalling in adipo-
cytes remains poorly characterised. Various AMPK activators have
been reported to reduce pro-inﬂammatory cytokine expression and
NFkB activation in adipose tissue from rodents (Jeong et al., 2009;
Sun et al., 2014) and inhibit expression and secretion of pro-
inﬂammatory cytokines in human subcutaneous WAT cultured ex-
vivo (Lihn et al., 2004, 2008). Importantly, however, these studiesdid not examine the effect of AMPK activation in adipocytes
themselves or demonstrate the AMPK-dependence of the AMPK
activators used. This is critical due to the non-speciﬁc nature of and
AMPK-independent effects reported for several widely-used AMPK
activators, including AICAR, phenformin and metformin (García-
García et al., 2010; Guigas et al., 2006). Three studies have re-
ported inhibition of IKKb phosphorylation in cultured adipocytes or
rodent adipose tissue by AMPK activators in a manner sensitive to
compound C, which has been used widely to imply AMPK-
dependence (Wang et al., 2013; Zhao et al., 2014; Chen et al.,
2016). Compound C is a poorly-selective inhibitor of AMPK, with
many reported AMPK-independent effects and inhibiting several
protein kinases other than AMPK with similar or greater potency
(Salt and Palmer, 2012; Bain et al., 2007). Indeed, compound C has
been demonstrated to inﬂuence pro-inﬂammatory signalling inde-
pendent of AMPK (Kim et al., 2011).
As AMPK is activated by several existing drugs used to treat type
2 diabetes, including metformin and thiazolidinediones (Bijland
et al., 2013), there is a need to understand the actions of AMPK
activation in metabolic tissues. Therefore, given the proposed anti-
inﬂammatory actions of AMPK and dearth of information con-
cerning the role of AMPK in adipocyte pro-inﬂammatory signalling,
we investigated the effect of AMPK activation on pro-inﬂammatory
signalling in response to IL-1b, TNF-a and IL-6, the principal cyto-
kines associated with adipose tissue inﬂammation, in cultured
adipocytes using the selective AMPK activator A769662, which
directly binds and activates AMPK heterotrimers containing the b1
non-catalytic subunit (Scott et al., 2008). We also examined basal
pro-inﬂammatory signalling pathway status in adipose tissue
lacking the AMPKa1 catalytic subunit.2. Materials and methods
2.1. Materials
3T3-L1 preadipocytes which overexpress the coxsackie virus
and adenovirus receptor (3T3-L1D1CAR) (Ross et al., 2003) were a
kind gift from Prof. David Orlicky, University of Colorado (CO, USA).
Adenoviruses expressing c-myc-tagged dominant negative mutant
AMPKa1 (Ad.a1-DN), constitutively active AMPKa1 (Ad.AMPK-CA),
GFP (Ad.GFP) and control adenoviruses (Ad.null) have been
described previously (Woods et al., 2000), and were a generous gift
from Dr F. Foufelle, Centre Biomedical des Cordeliers, Paris.
A769662 was obtained from Abcam (Cambridge, UK). [g-32P]-ATP
was obtained from Perkin Elmer (Buckinghamshire, UK). SAMS
peptide was obtained from GL Biochem Ltd (Shanghai, China).
Mouse IL-6 and mouse soluble IL-6 receptor-a (sIL-6Ra) were
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TNF-a and IL-1b were obtained from Sigma (Dorset, UK). Rabbit
anti-phospho-acetyl CoA carboxylase (ACC) S79, anti-phospho-
AMPK T172, anti-AMPKa, anti-JNK, anti-phospho-c-Jun S63, anti-
c-Jun, anti-phospho IkB S32, anti-phospho-IRAK4 T345/S346,
anti-IRAK4, anti-phospho-MKK4 S257, anti-MKK4, anti-STAT3,
anti-phospho IKKa/b S176/S177, anti-IKKb, anti-NFkB p65 anti-
bodies and mouse anti-phospho-JNK T183/Y185, anti-phospho-
STAT3 Y705 and anti-IkB antibodies were from New England Bio-
labs (Hitchin, Hertfordshire, UK). Mouse anti-myc (9E10) antibodies
were from Santa Cruz Biotechnology (California, US). Mouse anti-
GAPDH was obtained from Ambion (Cambridge, UK). Sheep anti-
ACC, anti-AMPKa1 and anti-AMPKa2 antibodies were a kind gift
from Prof. D. G. Hardie, University of Dundee (Dundee, UK). Donkey
Infrared dye-labelled secondary antibodies were from LI-Cor Bio-
sciences (Cambridge, UK). Goat anti-rabbit Alexa Fluor 488 sec-
ondary antibody was from Invitrogen (Paisley, UK). Mouse cytokine
20-plex panel for Luminex platform was obtained from Invitrogen
(Paisley, UK). All other reagents were from sources described pre-
viously (Ewart et al., 2008; Boyle et al., 2011).2.2. Cell culture
3T3-L1 and 3T3-L1D1CAR ﬁbroblasts were cultured and differ-
entiated into adipocytes as described previously (Boyle et al., 2011).
Human SW872 cells were cultured and differentiated into adipo-
cytes as described previously (Rios et al., 2015). Mouse embryonic
ﬁbroblasts (MEFs) lacking AMPKa1 and AMPKa2 (Laderoute et al.,
2006) and wild-type control MEFs were cultured in DMEM and
10% (v/v) FCS. 3T3-L1 preadipocytes were used between passages 8
and 12 and 8e12 days post differentiation. 3T3-L1D1 CAR pre-
adipocytes were used between passages 15 and 30 and 8e12 days
post differentiation. SW872 adipocytes were stimulated on day 9
post-differentiation having been serum-deprived overnight in
DMEM and 1% (v/v) NCS.2.3. Preparation of adenoviruses and infection of 3T3-L1D1CAR
adipocytes
Ad.a1-DN, Ad.AMPK-CA, Ad.GFP and Ad.null were propagated,
puriﬁed and titred as described previously (Ewart et al., 2008). 3T3-
L1D1CAR adipocytes were infected on day 6 post-differentiation
with adenoviruses in serum-free DMEM. After incubation for 4 h,
DMEM supplemented with 20% (v/v) FCS was added to achieve 10%
(v/v) ﬁnal concentration and the cells incubated for a further 48 h
prior to preparation of cell lysates.2.4. Confocal immunoﬂuorescence microscopy
Coverslips of 3T3-L1 or 3T3-L1D1CAR adipocytes were washed
with PBS and ﬁxed in 3% (w/v) paraformaldehyde at room tem-
perature for 20 min. Coverslips were thenwashed twice in PBS and
twice in 20 mmol/l glycine in PBS. Cells were incubated in per-
meabilisation media (PBS containing 2% (w/v) BSA, 0.1% (w/v)
saponin, 20 mmol/l glycine) for 20 min. Coverslips were incubated
in primary antibodies in permeabilisation media for 45 min,
washed in permeabilisation media four times and further incu-
bated in ﬂuorophore-conjugated secondary antibodies in per-
meabilisation media for 30 min. Cells were washed four times in
permeabilisation media, once in PBS and mounted on microscope
slides prior to visualisation on a Zeiss LSM 5 Pa Exciter laser scan-
ning microscope.2.5. Analysis of cytokine/chemokine production
3T3-L1D1CAR adipocytes infected with adenoviruses were
incubated in serum-free DMEM and stimulated with 10 ng/ml IL-1b
or a sIL-6Ra/IL-6 (25 ng/ml and 5 ng/ml, respectively) trans-sig-
nalling complex for 6 h with or without 30 min preincubation with
300 mmol/l A769662. After this incubation period, cells were
washed three times in serum-free DMEM and incubated with 0.4
ml/well DMEM for 1 h at 37 C, 10% (v/v) CO2. After 1 h, the
conditioned serum-free DMEM was collected and assayed for
cytokine/chemokine content using a Luminex mouse chemokine
20-plex bead immunoassay kit and a Luminex 100™ detection
system (Life Technologies, Paisley, UK), testing for the presence of
the cytokines GM-CSF, IFN-g, IL-1a, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-10,
IL-12, IL-13, IL-17 and TNF-a, the chemokines, CXCL1, CXCL9,
CXCL10 and MCP-1, basic ﬁbroblast growth factor (bFGF) and
vascular endothelial growth factor (VEGF).
2.6. RNA extraction from SW872 adipocytes and gene expression
analysis
RNA was extracted from SW872 adipocytes using an RNeasy kit
(Qiagen). Between 400 and 1000 ng of RNAwas reverse-transcribed
using the High Capacity cDNA Reverse Transcription kit (Applied
Biosystems). qPCR was performed with an Applied Biosystems ABI-
PRISM 7900HT Sequence Detection System. Gene expression was
normalised to TATA binding protein (TBP) using Assays on Demand
and QPCR master mix (Applied Biosystems). The following Taq-
Man® Gene Expression Assays (Applied Biosystems) were used:
TBP (Hs00427620_m1) and CXCL10 (Hs01124251_g1).
2.7. Preparation of cell lysates, SDS PAGE and immunoblotting
Cell lysates were prepared, proteins resolved by SDS-PAGE and
subjected to quantitative immunoblotting with the antibodies
indicated as described previously (Boyle et al., 2011). Immunola-
belled proteins were visualized using infrared dye-labelled sec-
ondary antibodies and an Odyssey Sa infrared imaging system
(LiCor Biosciences UK Ltd, Cambridge, UK). Band density was
quantitated with Image J software.
2.8. Immunoprecipitation and assay of AMPK activity
AMPK was immunoprecipitated from 3T3-L1 adipocyte lysates
using a mixture of sheep anti-AMPKa1 and anti-AMPKa2 anti-
bodies and assayed using the SAMS substrate peptide as previously
described (Boyle et al., 2011).
2.9. Oil red O staining of 3T3-L1 adipocytes
3T3-L1 adipocytes cultured on glass coverslips were incubated
in the presence or absence of A769662 (300 mmol/l). At various
intervals from the point of differentiation, cells were ﬁxed using
10% (v/v) formalin for 1 h, then washed once in 60% (v/v) iso-
propanol and left to dry completely. Coverslips were incubated in
5.1 mmol/l Oil Red O in 60% (v/v) isopropanol for 10 min before
washing four times with dH20 and left to dry. Dry coverslips were
then dipped in Mayers Hematoxylin (194 mmol/l KAl(SO4)2,
16.5 mmol/l hematoxylin, 2 mmol/l NaIO3, 2% (v/v) acetic acid),
followed by 3% (v/v) NH4OH for 10 s. Coverslips weremounted onto
slides and images captured using an Axiovision light microscope.
2.10. Animals
Female AMPKa1/ and wild-type sv129 mice (Jørgensen et al.,
S.J. Mancini et al. / Molecular and Cellular Endocrinology 440 (2017) 44e56 472004) were housed in a 12-h light dark cycle with access to food
(normal chow diet) and water ad libitum. All experimental pro-
cedures were performed in accordance with UK Home Ofﬁce
Guidance on the operation of the Animals (Scientiﬁc Procedures)
Act (1986), the “Guide for the Care and Use of Laboratory Animals”
published by the US National Institutes of Health (eighth edition)
and institutional ethical approval (PPL 70/8572, PPL60/4224).
2.11. Glucose tolerance test
Intraperitoneal glucose tolerance test was performed on 18e20
week old mice. Mice were fasted for 16 h prior to 1 g/kg intraper-
itoneal injection of D-glucose in 0.9% saline (Sigma). Blood glucose
levels were measured from tail samples with a glucometer (Free-
style Optium Xceed; Abbott, Berkshire,UK) at 0, 15, 30, 60 90 and
120 min.
2.12. Preparation of adipose tissue lysates
Mice (aged 18e20 weeks) were killed by cervical dislocation.
Subcutaneous and gonadal adipose tissue was excised and snap-
frozen prior to preparation of lysates as described previously
(Boyle et al., 2011).
2.13. Statistics
Results are expressed as mean ± SEM. Statistically signiﬁcant
differences were determined using a two-tail t-test, or one or two-
way ANOVA where appropriate, with p < 0.05 as signiﬁcant.
3. Results
Stimulation of 3T3-L1 adipocytes with 300e1000 mmol/l
A769662 or 1 mmol/l AICAR signiﬁcantly stimulated AMPK activity
(Fig. 1A), such that 300 mmol/l was used for subsequent experi-
ments. The stimulatory effect of A769662 was observed after
30 min incubation (Fig. 1B) To determine the effect of A769662 on
chemokine secretion, 3T3-L1D1CAR adipocytes were stimulated
with IL-1b at a concentration previously reported to stimulate IL-13
expression in 3T3-L1 adipocytes (Kwon et al., 2014) and chemo-
kine/cytokine secretion assessed using a murine chemokine
multiplex bead immunoassay and Luminex® 100™ detection sys-
tem. Of the 20 cytokines and chemokines assayed, IL-1b stimulation
markedly increased secretion of the chemokines CXCL1, CXCL10
and MCP-1. There was no detectable secretion of GM-CSF, IFN-g, IL-
1a, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17, TNF-a, CXCL9,
bFGF or VEGF in conditioned media from 3T3-L1D1CAR adipocytes
under basal or IL-1b-stimulated conditions. Intriguingly, A769662
abolished IL-1b-stimulated secretion of CXCL10, markedly reduced
MCP-1 secretion and modestly reduced IL-1b-stimulated CXCL1
secretion (Fig. 1CeE). Furthermore, pre-incubation of human
SW872 adipocytes with A769662 or the chemically-unrelated
AMPK activator AICAR attenuated IL-1b-stimulated CXCL10 mRNA
expression, at concentrations that activated AMPK activity, as
assessed by phosphorylation of the AMPK substrate, ACC (Fig. 2).
CXCL10, CXCL1 and MCP1 expression are stimulated by the
transcription factor NFkB and/or the AP-I transcription factor
complex which includes c-Jun. IL-1b stimulated the translocation of
NFkB p65 to the nucleus of 3T3-L1D1CAR adipocytes, an effect
markedly attenuated by preincubation for 30 min with A769662
(Fig. 3A and B). A769662-mediated inhibition of NFkB p65 nuclear
translocationwas ablated in 3T3-L1D1CAR adipocytes infectedwith
a dominant-negative AMPKa1 mutant (Ad.a1-DN) (Fig. 3CeE). Ef-
ﬁciency of adenoviral infection with Ad.a1-DN was estimated to be
approximately 60e70% and A769662-stimulated ACCphosphorylation was ablated in cells infected with Ad.a1-DN, as
assessed by myc immunoreactivity (Supplemental Fig. 1A). Infec-
tion with Ad.a1-DN was not sufﬁcient to inhibit A769662-
stimulated ACC phosphorylation in total 3T3-L1 adipocyte cell ly-
sates, however (data not shown). Furthermore, IL-1b-stimulated
p65 translocation was not observed in 3T3-L1D1CAR adipocytes
infected with a constitutively active AMPK mutant (Supplemental
Fig. 1B and C). Preincubation of 3T3-L1 adipocytes with A769662
signiﬁcantly attenuated IL-1b-stimulated JNK, IKK and IkB phos-
phorylation (Fig. 4). Furthermore, A769662 stimulation inhibited
both activating phosphorylation of the JNK kinase MKK4 in addi-
tion to autophosphorylation of the most upstream kinase in IL-1b
signalling, IRAK4 (Fig. 4).
Similar results were obtained when TNF-a was used as the pro-
inﬂammatory stimulus at concentrations previously demonstrated
to activate adipocyte proinﬂammatory signalling (Rotter et al.,
2003), with A769662 attenuating TNF-a-stimulated CXCL10
mRNA expression (Supplemental Fig. 2), NFkB p65 nuclear trans-
location (Supplemental Fig. 3) and IkB phosphorylation
(Supplemental Fig. 4) in cultured adipocytes. A769662 had no ef-
fect, however, on TNF-a-stimulated JNK phosphorylation
(Supplemental Fig. 4). Neither IL-1b nor TNF-a had any effect on
basal or A769662-stimulated AMPK activity, as assessed by ACC
phosphorylation (Fig. 4, Supplemental Fig. 4). The AMPK-
dependence of A769662-mediated inhibition of IL-1b-stimulated
IRAK4-MKK4-JNK signalling was further investigated in
AMPKa1a2/ and AMPKa1a2þ/þ MEFs. A769662 signiﬁcantly
inhibited IL-1b-stimulated phosphorylation of JNK, MKK4 and
IRAK4 in addition to the JNK substrate c-Jun in wild type
AMPKa1a2þ/þ MEFs, effects that were abolished in MEFs deﬁcient
in AMPKa (Fig. 5).
Increased IL-6 concentrations have been associated with insulin
resistance and obesity and, in contrast to IL-1b and TNF-a, signals
via a JAK-STAT mediated pathway (Lee et al., 2009; Salt and Palmer,
2012). A769662 signiﬁcantly inhibited STAT3 Tyr705 phosphory-
lation stimulated by a sIL-6Ra/IL-6 trans-signalling complex in 3T3-
L1 adipocytes (Fig. 6). sIL-6Ra/IL-6 had no effect on ACC phos-
phorylation (Fig. 6). Stimulation of 3T3-L1 adipocytes in the pres-
ence of IL-6 but without sIL-6Ra had no effect on STAT3 Tyr705
phosphorylation (data not shown). To examine whether A769662
stimulated tyrosine phosphatases, thereby reducing IL-6-
stimulated STAT3 phosphorylation, the capacity of A769662 to
inhibit IL-6-stimulated STAT3 phosphorylation was examined in
3T3-L1 adipocytes preincubated with the tyrosine phosphatase
inhibitor orthovanadate. Incubation with orthovanadate markedly
increased IL-6-stimulated STAT3 Tyr705 phosphorylation, yet this
was still markedly inhibited by A769662, indicating that AMPK-
mediated inhibition is at the level of JAK activity rather than
reduced STAT3 phosphatase activity (Supplemental Fig. 5).
In contrast to IL-1b, sIL-6Ra/IL-6-stimulation of 3T3-L1D1CAR
adipocytes did not produce detectable changes in cytokine/che-
mokine production (data not shown). Thus to examine the effect of
AMPK activation on a JAK-STAT mediated phenomenon in adipo-
cytes, the effect of A769662 on adipogenesis was examined. STAT3
Tyr705 phosphorylation occurred 24e48 h post-differentiation in
3T3-L1 adipocytes, an effect that was signiﬁcantly reduced in the
presence of A769662 (Fig. 7). A769662 had no signiﬁcant effect on
the early increase in expression of CEBPb or CEBPd during differ-
entiation, but did suppress the later (day4 onward) increase in
CEBPa and PPARg (Fig. 7). A769662 markedly inhibited the accu-
mulation of triglyceride during adipogenesis, as assessed by oil red
O staining (Fig. 7).
To determine the signiﬁcance of the suppressive effects of AMPK
on inﬂammatory signalling pathway status in adipose tissue in vivo,
JNK and STAT3 phosphorylationwere assessed in subcutaneous and
Fig. 1. AMPK activation suppresses IL-1b-stimulated chemokine secretion. 3T3-L1 adipocytes were (A) stimulated with the indicated concentrations of A769662 for 30 min or
1 mmol/l AICAR for 60 min and lysates prepared or (B) stimulated with 300 mmol/l A769662 for the indicated durations. AMPK was immunoprecipitated from lysates and assayed
for AMPK activity. Data shown represents AMPK activity (% vehicle) from 3 independent experiments. *p < 0.05 vs vehicle (two-tail t-test). (CeE) 3T3-L1D1CAR adipocytes infected
with Ad.Null were preincubated for 30 min in the presence or absence of A769662 (300 mmol/l) prior to stimulation in the presence or absence of IL-1b (10 ng/ml) for 6 h.
Conditioned medium was collected and chemokine secretion assayed using a multiplex bead immunoassay. Data shown represents IL-1b-stimulated (C) CXCL10 (D) CXCL1 or (E)
MCP-1 secretion from three independent experiments. ###p < 0.001 vs absence of IL-1b. **p < 0.01, ***p < 0.001 vs absence of A769662 (one way ANOVA).
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littermates. Fasting blood glucose, mass and glucose tolerance
were not signiﬁcantly different between genotypes (Supplemental
Fig. 6). Basal levels of both JNK and STAT3 phosphorylation were
signiﬁcantly increased in gonadal adipose tissue of AMPKa1/
mice relative to wild-type littermates. Basal STAT3 phosphorylation
was also signiﬁcantly increased in subcutaneous adipose tissue,
with JNK phosphorylation approaching signiﬁcance (p ¼ 0.054)
(Fig. 8).
4. Discussion
The principal ﬁndings of the study are that AMPK activation in
adipocytes inhibits multiple pro-inﬂammatory signalling path-
ways, including IL-1b-stimulated phosphorylation and activation of
MKK4/JNK and IKK/IkB/NFkB pathways, TNF-a-stimulated IKK/IkB/
NFkB and IL-6 trans-signalling-stimulated JAK-STAT3 signalling.
Furthermore, we demonstrate that AMPK-mediated suppression of
IL-1b-stimulated pro-inﬂammatory signalling in adipocytes is
associated with reduced phosphorylation of the key proximal IL-1b
signalling pathway protein IRAK4 as well as markedly reduced
expression and secretion of the chemokine CXCL10 by adipocytes.
Increased JNK and STAT3 phosphorylation is also observed in adi-
pose tissue depots from mice lacking AMPKa1, supportingregulation of these distinct pro-inﬂammatory signalling pathways
by AMPK in adipose tissue in vivo.
4.1. Inhibition of IKK-IkB-NFkB signalling by AMPK
In macrophages and macrophage cell lines, AMPK-dependent
inhibition of IkBa degradation and NFkB DNA binding has been
reported (Sag et al., 2008; Yang et al., 2010). Furthermore, increased
nuclear NFkB p65 levels have been reported in endothelial cells
frommice deﬁcient in AMPK subunits (Wang et al., 2010). Despite a
clear inhibitory role for AMPK in such cell types that constitute the
stromal-vascular fraction of adipose tissue, AMPK-dependent in-
hibition of IKK-IkB-NFkB signalling in adipocytes themselves has
not been conﬁrmed, although a compound C-sensitive inhibition of
NFkB and IKKb phosphorylation has been reported in cultured
adipocytes and perivascular adipose tissue (Sun et al., 2014; Chen
et al., 2016; Wang et al., 2013; Zhao et al., 2014). As compound C
inhibits several protein kinases and can inﬂuence pro-
inﬂammatory signalling independent of AMPK (Salt and Palmer,
2012; Kim et al., 2011; Bain et al., 2007), the current study com-
pliments these ﬁndings, by providing genetic evidence of the
AMPK-dependence of the inhibition of IL-1b and TNF-a-stimulated
NFkB p65 translocation in adipocytes. In endothelial cells, AMPK
has been proposed to inhibit NFkB signalling via phosphorylation of
Fig. 2. AMPK activators suppress IL-1b-stimulated CXCL10 mRNA expression in human
SW872 adipocytes. (A) Human SW872 adipocytes were stimulated with IL-1b (10 ng/
ml) for 6 h following preincubation for 30 min in the presence or absence of A769662
(0.1 mmol/l) or AICAR (1 mmol/l) and chemokine mRNA levels analysed by qPCR. Data
shown represents the % IL-1b-stimulated CXCL10 mRNA expression normalised to
TATA-binding protein from three independent experiments. ###p < 0.001 relative to
absence of IL-1b. **p < 0.01, *p < 0.05 relative to IL-1b alone (one-way ANOVA). (BeD)
SW872 adipocytes were stimulated with the indicated concentrations of A769662 or
AICAR for 30 min and lysates prepared. Lysate proteins were resolved by SDS-PAGE and
subjected to immunoblotting with the antibodies indicated. (B) Representative im-
munoblots repeated on two further occasions with similar results. (C, D) Densitometric
analysis of ACC phosphorylation relative to GAPDH levels from three independent
experiments. *p < 0.05 relative to absence of A769662 (one-way ANOVA).
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acetylation of NFkB p65 (Zhang et al., 2011), however this report did
not investigate the effect of AMPK activation upstream of NFkB.
Alternatively, AMPK has also been proposed to hyperphosphorylate
and inactivate IKK, thereby suppressing NFkB signalling (Bess et al.,
2011). The ﬁndings in the current study do not fully support either
of these mechanisms, as the rapid A769662-mediated inhibition of
the NFkB pathway is associated with inhibition of activating IKK
phosphorylation in adipocytes rather than hyperphosphorylation.
4.2. AMPK-mediated inhibition of JNK phosphorylation
Whether AMPK negatively regulates proinﬂammatory JNK sig-
nalling is far less well characterised. AMPK-dependent inhibition of
JNK phosphorylation has been reported in macrophages (Jeong
et al., 2009) and increased JNK phosphorylation has been re-
ported in macrophages and endothelial cells frommice deﬁcient in
AMPK subunits (Galic et al., 2011; Dong et al., 2010). The AMPK
activator AICAR has been previously reported to suppress basal JNK
phosphorylation in 3T3-L1 adipocytes and adipose tissue of mice
(Miyokawa-Gorin et al., 2012; Shibata et al., 2013). Despite this, the
mechanism by which AMPK inhibits activating JNK phosphoryla-
tion has not been reported. In the current study, A769662 directly
inhibited phosphorylation of the JNK kinase MKK4 in MEFs in an
AMPK-dependent manner, demonstrating the inhibition is not due
to increased JNK phosphatase activity. This is in agreement with
indirect evidence in a study published when this manuscript was in
preparation, in which hearts of mice with a cardiac-speciﬁc knock
in of a kinase-dead AMPKwere reported to exhibit increased MKK4
phosphorylation after ischaemia-reperfusion (Zaha et al., 2016).
Furthermore, we show increased basal JNK phosphorylation in
adipose tissue depots from mice lacking AMPKa1, reinforcing the
negative regulation of pro-inﬂammatory JNK signalling by AMPK
in vivo. Intriguingly, A769662 was unable to suppress TNF-a-stim-
ulated JNK phosphorylation in 3T3-L1 adipocytes, indicating a
cytokine-speciﬁc effect of AMPK activation. This is in agreement
with previous studies where AICAR inhibited TNF-a-stimulated
ERK1/2 phosphorylationwithout impairing JNK phosphorylation in
3T3-L1 adipocytes (Shibata et al., 2013) and A769662 inhibited
palmitate-stimulated IKK phosphorylationwithout inﬂuencing JNK
phosphorylation in L6myotubes (Green et al., 2011). Taken together
with the current study, this suggests inhibition of MKK4/JNK and
IKK/IkB/NFkB pathways is not mediated by a common AMPK target
shared by both pathways.
4.3. AMPK-mediated inhibition of IRAK4 phosphorylation
We demonstrate that A769662 stimulation inhibits IL-1b-stim-
ulated phosphorylation of IRAK4 at Thr345/Ser346, a proximal
event in IL-1b signalling that is not common with TNF-a signalling
(Flannery and Bowie, 2010; Salt and Palmer, 2012). This shows that
AMPK activation impairs IL-1b signalling at a more early stage than
previously reported. It is feasible; therefore, that inhibition of JNK
signalling by AMPK activation is dependent on impaired IRAK4
autophosphorylation. As IRAK4 phosphorylation is a signalling
event shared by several toll-like receptors (Flannery and Bowie,
2010), AMPK activation should also inhibit signalling by other in-
ﬂammatory stimuli that utilise IRAK4.
4.4. Inhibition of JAK-STAT signalling by AMPK
IL-6-stimulated STAT3 phosphorylation has been reported in
liver-derived cells, which utilise the classical membrane-bound IL-
6 receptor (Nerstedt et al., 2013; Kim et al., 2012). In contrast, IL-6
was only effective in 3T3-L1 adipocytes when administered with
Fig. 3. AMPK activation inhibits IL-1b-stimulated NFkB p65 nuclear translocation. (A,B) 3T3-L1 adipocytes were incubated with IL-1b (10 ng/ml, 15 min) following preincubation for
30 min in the presence or absence of A769662 (300 mmol/l). (CeE) 3T3-L1D1CAR adipocytes were infected with 600 ifu/cell (C) Ad.null or (D) Ad.a1DN for 48 h prior to stimulation
as in (A). NFkB p65 localisation was assessed by confocal ﬂuorescence microscopy, with Ad.a1DN-infected cells identiﬁed with anti-myc antibody. (A, C, D) Representative images
are shown. (B, E) Densitometric quantiﬁcation of nuclear NFkB p65 ﬂuorescence. All data are presented as % IL-1b-stimulated nuclear ﬂuorescence from three independent ex-
periments with >50 cells analysed for each treatment in each experiment. Myc-positive Ad.a1DN infected cells only were analysed for ﬁlled bars in panel E. ###p < 0.001, ##p < 0.01
vs absence of IL-1b; ***p < 0.001 vs absence of A769662 (one-way ANOVA).
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more, we demonstrate that A769662-mediated inhibition of STAT3
phosphorylation occurred 24e48 h post-differentiation in the
mitotic clonal expansion (MCE) phase concomitant with reduced
lipid accumulation. Transient elevation in STAT3 phosphorylation
in the MCE phase is essential for adipocyte differentiation (Wang
et al., 2009). This represents an earlier mechanism by which
AMPK activation may inhibit adipogenesis than the reduced
expression of later adipogenic markers previously reported
(Habinowski and Witters, 2001). AMPK activation by A769662
rapidly attenuates IL-6-stimulated STAT3 phosphorylation in the
presence of the tyrosine phosphatase inhibitor vanadate, indicating
an effect on JAK activity, in agreement with studies in liver cell lines
(Nerstedt et al., 2013). This is further corroborated by recent studies
in our laboratories that have demonstrated that AMPK can directly
phosphorylate Ser515 and Ser518 in JAK1 in vitro, and that muta-
tion of the Ser residues to Ala ablates AMPK-mediated inhibition of
JAK1-STAT signalling in intact cells (Rutherford et al., 2016).
A769662-mediated inhibition of JAK activity via phosphorylation of
Ser515/518 is therefore likely to underlie the inhibition of both IL-6signalling and adipogenic JAK-STAT signalling.4.5. Inhibition of cytokine/chemokine synthesis by AMPK activation
A769662 suppressed IL-1b-stimulated secretion of MCP-1,
CXCL10 and CXCL1 from 3T3-L1D1CAR adipocytes in addition to
IL-1b- and TNF-a-stimulated CXCL10 gene expression in SW872
adipocytes. AMPK-dependent inhibition of MCP-1 secretion has
previously been demonstrated in several cell types (Salt and
Palmer, 2012; Ewart et al., 2008). The current study supports and
extends previous studies reporting AMPK-mediated inhibition of
IFN-g-stimulated CXCL10 mRNA expression in mouse astrocytes
and microglia (Meares et al., 2013). When examining the cytokines
and chemokines inﬂuenced by IL-1b in adipocytes, it has previously
been reported that IL-1b stimulates MCP-1 secretion in 3T3-L1
adipocytes (Takahashi et al., 2008) and a recent study in human
differentiated adipocytes reported IL-1b-stimulated secretion of
MCP-1 and CXCL10 (Alomar et al., 2015). The latter study also re-
ported IL-1b-stimulated secretion of IL-2, IL-4, IL-6, IL-10, IL-13, IL-
17, IFN-g, TNF-a, VEGF and GM-CSF, which was not observed in the
Fig. 4. A769662 rapidly inhibits IL-1b-stimulated JNK, IRAK4, IKK and IkB phosphorylation in 3T3-L1 adipocytes. 3T3-L1 adipocytes were incubated for 30 min in the presence or
absence of A769662 (300 mmol/l) prior to stimulation with IL-1b (10 ng/ml) for the indicated durations. Lysate proteins were resolved by SDS-PAGE and subjected to immuno-
blotting with the antibodies indicated. (A,C,E,G) Representative immunoblots. (B,D,F,H) Densitometric analysis of three independent experiments for (B) JNK (p54), D) IRAK4, (F)
IKKa/b and (H) IkBa phosphorylation normalised to respective total levels in each case. ###p < 0.001 vs absence of IL-1b. ***p < 0.001, **p < 0.01, *p < 0.05 vs absence of A769662
(two-way ANOVA).
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may reﬂect the two different cell models, shorter exposure to IL-1b
in our study or differential sensitivity of the assays utilised. CXCL10
is transcriptionally regulated by NFkB and pro-inﬂammatory MAPKsignalling (Thiefes et al., 2005). As A769662 had no effect on TNF-a-
stimulated JNK phosphorylation yet robustly inhibited CXCL10
mRNA expression, this may suggest that inhibition of the IKK-IkB-
NFkB pathway underlies the inhibition in TNF-a-stimulated cells.
Fig. 5. A769662-mediated inhibition of MKK4, JNK and NFkB pathway signalling is AMPK-dependent. Wild-type (AMPKþ/þ) and AMPK-deﬁcient (AMPK/) MEFs were incubated
for 30 min in the presence or absence of A769662 (100 mmol/l) prior to stimulation with IL-1b (10 ng/ml, 15 min). Lysate proteins were resolved by SDS-PAGE and subjected to
immunoblotting with the antibodies indicated. A) Representative immunoblots. (BeD) Densitometric analysis of (B) MKK4 relative to GAPDH or (C) JNK (p46), (D) IRAK4 phos-
phorylation normalised to respective total levels in each case from three (B,D) or four (C) independent experiments. ###p < 0.001, ##p < 0.01 vs absence of IL-1b, **p < 0.01, *p < 0.05
vs absence of A769662 (one-way ANOVA).
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Fig. 6. A769662 rapidly inhibits sIL-6Ra/IL-6-stimulated STAT3 phosphorylation in
3T3-L1 adipocytes. 3T3-L1 adipocytes were incubated for 30 min in the presence or
absence of A769662 (300 mmol/l) prior to stimulation with IL-6/sIL-6Ra (5 ng/ml,
25 ng/ml) for the indicated durations. Lysate proteins were resolved by SDS-PAGE and
subjected to immunoblotting with the antibodies indicated. (A) Representative im-
munoblots and (B) densitometric analysis of phospho-STAT3 relative to total STAT3
from six independent experiments. yyyp < 0.001, yp < 0.05 vs absence of sIL-6Ra/IL-6;
***p < 0.001, *p < 0.05 vs absence of A769662 (two-way ANOVA).
Fig. 7. A769662 inhibits STAT3 Tyr705 phosphorylation during adipogenesis. 3T3-L1
adipocytes were differentiated in the presence or absence of A769662 (300 mmol/l).
Lysates were prepared at various intervals post-differentiation and immunoblotted
with the antibodies indicated. (A) Representative immunoblots. B) densitometric
analysis of STAT3 phosphorylation relative to total STAT3 levels from four independent
experiments. ###p < 0.001, #p < 0.05 vs undifferentiated; *p < 0.05 vs absence of
A769662 (two-way ANOVA). (C) Cells were ﬁxed and stained with oil red O at various
intervals post differentiation. Representative microscope images are shown (scale
bar ¼ 50 mm).
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mice with reduced AMPK levels
As increased JNK and STAT3 phosphorylation was observed in
adipose tissue depots from mice lacking AMPKa1, this indicates
that these distinct pro-inﬂammatory signalling pathways are
negatively regulated by AMPK in adipose tissue in vivo. In support
of this, increased myocardial cytokine and chemokine expression
has previously been demonstrated in the same mouse model after
LPS stimulation (Castanares-Zapatero et al., 2013). As the mouse
adipose used in the current study is from mice globally deﬁcient in
AMPKa1, the increased basal JNK and STAT3 phosphorylation
observed may be a consequence of impaired AMPK activity in ad-
ipocytes, macrophages or other stromal-vascular cells. The effect
was not due to differences in mass or glucose tolerance, which was
unaltered between genotypes. Mice with adipocyte-speciﬁc dele-
tion of AMPKa1, AMPKa2, AMPKb1 and AMPKb2 have recently
been described (Wu et al., 2015; Mottillo et al., 2016) which would
prove useful in order to further characterise the anti-inﬂammatory
actions of AMPK in adipose.4.7. Activation of AMPK in adipocytes
The concentration of A769662 (300 mmol/l) required for acti-
vation of AMPK in 3T3-L1 adipocytes and SW872 adipocytes is
higher than that previously reported in several other tissues and
cell types (G€oransson et al., 2007; Foretz et al., 2010), although this
concentration does not inappropriately alter AMP:ATP ratios in
HEK293 cells (Hawley et al., 2010). As a few studies have reported
AMPK-independent effects of A769662 in other cell types (García-
García et al., 2010; Benziane et al., 2009; Moreno et al., 2008), the
demonstration of AMPK-dependent inhibition of signalling using
dominant negative mutant AMPK and MEFs lacking AMPK estab-
lishes the AMPK dependence of these effects.Reduced AMPK activity has been reported in metabolic tissues
of animal models of insulin resistance and obesity (Viollet et al.,
2010; Coughlan et al., 2014). Furthermore, reduced AMPK activity
has been reported in adipose tissue of insulin resistant volunteers
compared with BMI-matched insulin sensitive controls (Gauthier
et al., 2011) and weight loss is associated with increased adipose
tissue AMPK activity and insulin sensitivity (Fritzen et al., 2015; Xu
et al., 2015), although SCAT TNF-a and IL-1b mRNA levels were
unchanged after weight loss (Xu et al., 2015). Multiple lines of ev-
idence suggest activation of AMPK is a useful therapeutic aim in
obesity and insulin resistance. Activation of adipose tissue AMPK is
feasible, as previous work in our laboratory has shown that met-
formin stimulated AMPK activity in SCAT of individuals with type 2
diabetes (Boyle et al., 2011).
4.8. Conclusions
Taken together, our data demonstrate that AMPK activation is
Fig. 8. Adipose tissue from mice lacking AMPKa1 exhibit increased JNK and STAT3
phosphorylation. Gonadal or subcutaneous (Subcut) adipose tissue lysates from
AMPKa1 knockout (KO) or wild-type (WT) mice were subjected to immunoblotting
with the antibodies indicated. (A) Representative immunoblots shown. (B) Densito-
metric analysis of mean ± SEM JNK (p54) phosphorylation and STAT3 phosphorylation
relative to total JNK or STAT3 levels from 8 to 9 WT and 6e7 KO animals with the
number of animals in each case indicated in parentheses. ***p < 0.001, *p < 0.05 vs WT
(two-tailed t-test).
S.J. Mancini et al. / Molecular and Cellular Endocrinology 440 (2017) 44e5654associated with multiple anti-inﬂammatory actions in adipocytes
including inhibition of IL-1b-stimulated IRAK4 phosphorylation.
Such anti-inﬂammatory actions would be likely to improve theinsulin resistance associated with obesity in addition to the well-
characterised metabolic actions of AMPK. Accordingly AMPK in
adipose tissue is a therapeutic target worthy of further
investigation.
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